S. 1095 · 119th Congress · Health
Stop STALLING Act
Bill title suggests addressing delays, but summary unavailable to determine specific policy. AI-read
- IntroducedMar 24, 2025 Done
- CommitteeReported Apr 10, 2025 Done
- Senate floorAwaiting vote Current stage
- House floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
This bill makes it an unfair method of competition to submit an objectively baseless petition to the Food and Drug Administration (FDA) in an attempt to interfere with a competitor's application for market approval of a drug.
The bill authorizes the Federal Trade Commission to sue an individual or entity that submits such a petition to the FDA. A party found liable in such a lawsuit is subject to civil penalties, such as a fine of up to $50,000 for each day that the FDA spent reviewing the baseless petition.
Congressional Research Service · summary of “Introduced in Senate” version · Mar 24, 2025
Who lobbies on it
11 organizations · 61 filings · Q1 2025–Q3 2026One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Pharmaceutical Research and Manufacturers of America
7 of 7 quarters
“Issues related to competition pracitces in the pharmaceutical marketplace. S.1040 - Drug Competition Enhancement Act. S.1041 - Affordable Prescriptions for Patients Act. S.2658 - Medication Affordability and Patent Integrity Act (MAPIA). S.1095 - Stop STALLING Act. S.43 - Skinny Labels, Big Savings Act.”
-
America's Health Insurance Plans Inc (ahip)
7 of 7 quarters
“H.R. 1 - One Big Beautiful Bill Act - Rep. Arrington, Jodey - Medicaid eligibility and state financing, Marketplace coverage and enrollment, Health Savings Account expansion, Pharmacy Benefit Manager financing and regulation H.R. 843 - Prompt Approval of Safe Generic Drugs Act - Rep. Barragan, Nanette Diaz - Generic…”
-
Guidewell Mutual Holding Corporation
7 of 7 quarters
“Issues: Generics access; Prescription Drug Cost; PBM Reform and Prescription Drug Policy Bills: S.1954 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S.3014 - Ensuring…”
8 more organizations, every filingPROUpgrade
Organizations that named S. 1095 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. Source: Senate lobbying disclosures (LD-2) from lda.gov; quotes are word for word from the “specific lobbying issues” field.
Actions
5 actions · newest first- Apr 10, 2025Placed on Senate Legislative Calendar under General Orders. Calendar No. 45.
- Apr 10, 2025Committee on the Judiciary. Reported by Senator Grassley without amendment. Without written report.
- Apr 3, 2025Committee on the Judiciary. Ordered to be reported without amendment favorably.
- Mar 24, 2025Read twice and referred to the Committee on the Judiciary.
Show all 5 actionsShow fewer
- Mar 24, 2025Introduced in Senate
What members said about it
-
Senate Judiciary Committee Advances Six Bipartisan Bills To Lower Prescription Drug Prices
This morning, the U.S. Senate Judiciary Committee advanced six bipartisan bills to help lower the price of prescription drugs.
“Families are struggling to afford their medications. Congress must take an all-options approach to lowering prescription drug prices, and the bills we advanced today embody that spirit. The legislative package will improve coordination between agencies, bring generic drugs to market more quickly, and foster competition…”